BIOC Biocept Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIOC

Price (delayed)

$2.16

Market cap

$1.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$56.7

Enterprise value

$6.09M

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, including metastatic tumors involving ...

Highlights
The debt has decreased by 6% YoY and by 4.3% QoQ
BIOC's gross profit has dropped by 140% year-on-year
BIOC's equity has dropped by 93% year-on-year and by 73% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.biocept.com
Peers: EXAS VCYT MYGN

Key stats

What are the main financial stats of BIOC
Market
Shares outstanding
592,906
Market cap
$1.28M
Enterprise value
$6.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
0.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
Earnings
Revenue
$11.38M
EBIT
-$32.05M
EBITDA
-$30.06M
Free cash flow
-$19.35M
Per share
EPS
-$56.7
Free cash flow per share
-$32.95
Book value per share
$4.27
Revenue per share
$19.37
TBVPS
$39.15
Balance sheet
Total assets
$22.99M
Total liabilities
$20.57M
Debt
$11.58M
Equity
$2.43M
Working capital
$4.7M
Liquidity
Debt to equity
4.77
Current ratio
2.07
Quick ratio
1.8
Net debt/EBITDA
-0.16
Margins
EBITDA margin
-264.2%
Gross margin
-85.8%
Net margin
-283.3%
Operating margin
-282.5%
Efficiency
Return on assets
-83.9%
Return on equity
-208.3%
Return on invested capital
-111.6%
Return on capital employed
-172.3%
Return on sales
-281.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOC stock price

How has the Biocept stock price performed over time
Intraday
-6.9%
1 week
-67.52%
1 month
686.03%
1 year
54.29%
YTD
307.55%
QTD
535.29%

Financial performance

How have Biocept's revenue and profit performed over time
Revenue
$11.38M
Gross profit
-$9.76M
Operating income
-$32.14M
Net income
-$32.23M
Gross margin
-85.8%
Net margin
-283.3%
BIOC's gross profit has dropped by 140% year-on-year
Biocept's operating margin has plunged by 128% from the previous quarter
The net margin has shrunk by 128% QoQ
Biocept's revenue has shrunk by 82% YoY and by 56% QoQ

Growth

What is Biocept's growth rate over time

Valuation

What is Biocept stock price valuation
P/E
N/A
P/B
0.51
P/S
0.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
BIOC's equity has dropped by 93% year-on-year and by 73% since the previous quarter
The stock's price to book (P/B) is 72% less than its 5-year quarterly average of 1.8 and 58% less than its last 4 quarters average of 1.2
The price to sales (P/S) is 96% lower than the 5-year quarterly average of 2.7 and 73% lower than the last 4 quarters average of 0.4
Biocept's revenue has shrunk by 82% YoY and by 56% QoQ

Efficiency

How efficient is Biocept business performance
The company's return on sales has shrunk by 128% QoQ
Biocept's ROE has plunged by 57% from the previous quarter
BIOC's return on assets is down by 26% since the previous quarter
The return on invested capital has declined by 8% since the previous quarter

Dividends

What is BIOC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOC.

Financial health

How did Biocept financials performed over time
BIOC's total assets is 12% higher than its total liabilities
BIOC's total assets has shrunk by 63% YoY and by 26% QoQ
Biocept's quick ratio has decreased by 42% YoY and by 34% from the previous quarter
BIOC's equity has dropped by 93% year-on-year and by 73% since the previous quarter
The debt has decreased by 6% YoY and by 4.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.